Ulcerated hemosiderinic dyschromia and iron deposits within lower limbs treated with a topical application of biological chelator

Eugenio Brizzi,1 Marcelo Castro,2 Marina Narbalitz, Natalia Borda,3 Claudio Carbia,4 Laura Correa,4 Roberto Mengarelli,3 Amalia Merelli,2 Valeria Brizzi,2 Maria Sosa,6 Biagio Biancardi,7 Alberto Lazarowski2

Abstract

The ulcerative hemosiderinic dyschromia of chronic venous insufficiency is difficult to heal and presents a high accumulation of iron. Lactoferrin, a potent natural iron chelator, could help to scar this ulcerative hemosiderinic dyschromia. The objective of this study was to determine whether the topical application of a liposomal gel with Lactoferrin favors scarring/degradation of the brown colored spot typical of ulcerative hemosiderinic dyschromia. Nine patients with severe chronic venous insufficiency and ulcerative hemosiderinic dyschromia (CEAP-C6), with a natural evolution of over 12 months, were included in the study. Hemochromatosis gene mutations were investigated. The levels of serum ferritin, transferrin saturation and blood cell counts were analyzed. The presence of hemosiderin was investigated through periculcerous and ulcer fundus biopsies carried out at baseline and 30 days after treatment with Lactoferrin. The severity of the injuries (CEAP classification) was evaluated at the beginning of and throughout the whole 3-month treatment period. No patient had received compression treatment during the three months previous to this therapy. Significant improvement in these injuries, with a reduction in the dimensions of the brown spot (9 of 9) at Day 90, and complete scarring with a closure time ranging from 15 to 180 days (7 of 9) were observed. The use of topical lactoferrin is a non-invasive therapeutic tool that favors clearance of hemosiderinic dyschromia and scarring of the ulcer. The success of this study was not influenced either by the hemochromatosis genetics or the iron metabolism profile observed.

Introduction

Chronic venous insufficiency (CVI) is one of the most significant health problems in developed countries. Though the pathogenesis of skin changes and venous ulcers is not completely understood, they occur as a late consequence of chronic ambulatory venous hypertension, caused by outflow obstruction and reflux due to superficial or deep venous valve incompetence. Ethological theories including fibrin cuffs or leukocyte entrapment by chronic inflammation have been suggested.1

Hemochromatosis dyschromia (HD) of CVI is a pathological entity that features a brown colored spot resulting from the deposit of free iron within leg tissues. Iron is a highly irritant element capable of stimulating free-radical release and of causing leg ulcers, thus producing an ulcerated hemosiderinic dyschromia (UHD). Since it has been recognized as a grade IV cause of skin dyschromia according to CEAP classification, and taking into account that these effects can be self-produced or generated by stimulation of melanin, there is an increasing interest in the role of iron tissue deposits caused by chronic venous disorders. According to this, a brown discoloration of the skin near the injury can be considered to be a typical sign of venous disease. It occurs when blood cells leak out of blood vessels. The hemoglobin from red blood cells is broken down into hemosiderin that is then permanently stored within the tissues. This can take place after a significant injury in the leg and is often worsened by an underlying venous problem.2,3

Since extravasated blood cells with hemosiderin are phagocyted by tissue macrophages called siderophages, the accumulation of hemosiderin within the injury area is a characteristic feature of the disease, resulting in the brownish color of the skin.4 Furthermore, urinary hemosiderin could be a biological marker for the clinical follow up of chronic venous insufficiency with hemosiderinic dyschromia.5

Nearly 25% of absorbed iron is normally eliminated from the body by exfoliation of epidermal cells; therefore, iron accumulation in the skin should be secondary to any mechanism that may increase iron deposits before carrying out this exfoliation. Iron is thought to be a co-factor or mediator of skin toxicity in a variety of pathological situations, including sunburn,1 porphyria cutanea tarda,2 inflammation,3 and skin cancer,4 as well as in hereditary hemochromatosis (HH).6 It is important to distinguish HD in CVI from hereditary HH because individual differences could be genetically determined by genes related to HH (H63D, S65C and C282Y).7

Lactoferrin (LFR) is a glycoprotein belonging to the family of transferrins, capable of binding to iron. Both human and bovine LFR show a wide antimicrobial spectrum, against positive and negative Gram bacteria, and certain viruses and fungi.8 The studies on LFR have focused on its ability to chelate iron in cases of hemosiderinic iron accumulation (ecchymosis, post sclerotherapy, CVI).9 The results of recent studies indicate that it is a powerful regulator of dermal fibroblasts, and that it promotes cutaneous wound healing;10,11

Key words: ulcerated hemosiderinic dyschromia, liposomal Lactoferrin, scarring, hemosiderin-ferritin.

Acknowledgments: the authors would like to thank P. Girimonte for her assistance with the statistical analysis of the results. We also wish to thank the patients who made this study possible.

Conference presentation: part of the present study has been presented at the following congresses: i) XX Argentine Congress of Hematology, October 18–22, 2011, Mar Del Plata, Argentina (submitted to the Poster Section); ii) III World Symposium of advances in Phlebology and Lymphology, November 10–12, 2011, Buenos Aires, Argentina (awarded); iii) Latin American Congress of Angiology and Vascular Surgery, November 24th, 2011, Cartagena, Colombia.

Received for publication: 26 July 2012. Revision received: 19 September 2012. Accepted for publication: 26 September 2012.

This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0).

©Copyright E. Brizzi et al., 2012

Licensee PAGEPress, Italy

Veins and Lymphatics 2012; 1:e6
doi:10.4081/vl.2012.e6
however, this has been poorly researched.

There is currently no efficient treatment for HD and associated ulcer in patients with CVI. In a recent systematic survey and meta-analysis, eight randomized clinical trials were identified comparing treatment with stockings and bandages. Five studies revealed an advantage in the use of stockings over bandages, while three other assays showed no difference.15

Our aim was to study the effect of liposomatemed bovine Lactoferrin, locally applied on the surface of UHD, in 9 patients with long-lasting evolution of refractory CVI, selected from our previous study,16 and to evaluate its potential relation to the iron metabolism profile and mutations of HH genes.17

Study design
This was a prospective controlled pilot study performed on 9 selected patients with severe and persistent UHD of CVI, carried out according to the inclusion and exclusion criteria described below.

All patients gave their signed individual consent to treatment with topical application of liposomatemed LFR and to undergo biopsy of two lesions. There were three evaluation time points: at 30, 90 and 180 days. The therapeutic protocol was presented for review by the independent court of ethics on March 5th 2010 and was accepted on April 23th 2010; the protocol was approved in accordance with the principles of the Declaration of Helsinki.

The study used a database consistent with the results obtained during a 6-month follow-up period of 9 patients with recalcitrant venous ulcers. Only one of them presented bilateral ulcers with similar severity of lesions in both legs. This was a pilot study and the data collected should be considered in this light.

The main parameters controlled before and after treatment were: i) stratification of CVI (Ecodoppler), and leg goniometry and edema; ii) severity of ulcerous injuries (color; ulcer areas, rate of scarring time); iii) pain and quality of life; iv) hemosiderin staining in biopsies and blood iron metabolism parameters; v) hematologic profiles; vi) iron profiles; vii) the presence of HH mutations as potential predictive parameters of evolution.

Inclusion criteria
The main inclusion criteria were: i) patients over 18 years old; ii) unilateral or bilateral ulcers at the anteromedial part of the calf, of proved venous origin, confirmed by Ecodoppler ultrasound; iii) surface larger than 3 cm² and smaller than 25 cm²; iv) presence of associated periulcerative haemosiderinic dyschromia; v) pre-existing ulcer with at least two months of evolution; vi) patients accepting to undergo treatment according to protocol; vii) each patient received a written report and signed their consent.

Exclusion criteria
The main inclusion criteria were: i) presence of occlusive arterial pathology with a more than 0.8 arm/ankle index; ii) known allergies; iii) pregnancy; iv) life expectancy less than 12 months; v) severe diseases co-existing simultaneously with venous pathologies, e.g. cardiac or mental disorders, renal or hepatic insufficiencies, tumors, etc.; vi) symptomatic peripheral neuropathy, e.g. diabetic neuropathy; vii) patients with motor disabilities; viii) diabetes; ix) severe joint disease of the ulcerated leg, besides the ankle stiffness caused by venous ulceration.

Materials and Methods

Patients
Nine patients were selected (3 males, 6 females); average age 63 years. A total of 10 ulcerated legs were studied (unilateral ulcers, n=8; bilateral ulcers, n=2).

Ecodoppler
A SonoScape® colour Ecodoppler S6 (SonoScape Co. Ltd., Shenzhen, China) was used to confirm the venous vascular etiology of the ulcer and the stratification of patients according to the type of reflux observed. Only one baseline control was performed at the moment of admission. Stratification of patients was carried out according to the type of reflux observed, such as superficial, perforating, deep, or their combined forms as superficial + perforating, perforating + deep, superficial + perforating + deep.

Lesion evaluation
Time from the onset of the CVI, the evolution of the hemosiderinic dyschromia, and the ulcer development were all recorded.

Since skin pigmentation as a brown discoloration near the lesion is a typical feature of HD in case of venous ulcers, a visual scale of brown color was used to follow up treatment. Baseline and weekly controls were carried out. We used an analogical visual arbitrary numbered scale of brown (Figure 1) that allowed us to build a follow-up chart and to identify any improvement in HD.

Wound size is a basic parameter used to evaluate the success of treatment. The planimetric Visitrak® Smith and Nephew device (Smith and Nephew, Hull, UK) was used.

Volume was obtained through perimeters measured at 4 segments of the leg: 12 cm from hallux extremity, and 10, 20 and 30 cm from the floor (Figure 2A and B).16,17

Goniometry was measured using the model described by Cleusa Belczak (Figure 3).20

Pain was measured at baseline and after four weeks of treatment using the arbitrary numerical Likert scale from 1 to 5, where 1 indicates the lowest intensity of pain and 5 the highest one.21 The quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ) was evaluated as previously described.22

Venous blood samples for determining hematimetric parameters as well as molecular studies were drawn in 2 separate collection tubes containing potassium ethylene diamine tetracetic acid (K₃-EDTA), while those for determining biochemical parameters were drawn in tubes with serum separators. Serum was freshly separated from venous blood samples by centrifugation at 1800 g for 10 min at room temperature. All fractioned serum samples and those for molecular studies were stored frozen at -20°C for three months before assaying. Hematimetric parameters were evaluated on fresh samples immediately after blood sample collection; full blood cell counts were studied by SYSMEX XT-1800i (Roche, Penzberg, Germany). Serum iron (SFe, µg/dL), total iron-binding capacity (TIBC, µg/dL), transferrin saturation (sat-Trf %) and serum ferritin (SF, ng/mL) were assayed using a Cobas 6000 autoanalyzer system (Roche).

Figure 1. Arbitrary identification of color scale used.
HFE genotyping

Samples: five drops of 25 μL of anticoagulated blood with K2-EDTA were collected on Whatman filter paper no. 1 (5x5 cm) and stored at room temperature in a paper envelope.

DNA extraction: DNA was extracted by the modified Boom method. Two drops of dried blood from filter paper of each sample were cut with a scalpel and placed on 4.5 mL of lysis buffer. After 4 h of gentle shaking, the paper was carefully discarded and the DNA was extracted in the supernatant as previously described.

DNA extracts were stored at -20 °C.

Amplification and detection: the polymerase chain reaction (PCR) mixture was prepared in separate tubes for the study of mutations in exons 4 and 2, respectively, at a final volume of 50 μL and a final concentration of 1X Taq Buffer, 0.2 mM dNTP, 2.5 mM MgCl2, 0.5 U of Taq polymerase (Invitrogen Corp., Carlsbad, CA, USA) and 0.2 μM of each primers (Invitrogen). We used 5 μL of DNA extract per sample. The sequences of the primers used were:

i) exon 4 (Cys282Tyr mutation)
   - Forward: 5'GCCACCATCTGGCTTGAAATT (208 bp).
   - Reverse: 5'CTCAGGCACTCCTCTCAACC (390 bp);

ii) exon 2 (mutations His63Asp and Ser65Cys)
   - Forward: 5'ACATGGTTAAGGCCTGTTGC
   - Reverse: 5'TGGCAAGGGTAAACAGATCC

For both constructions of primers, amplification conditions were 35 cycles with an initial denaturation at 94 °C for 5 min, annealing at 56 °C for 30 s, and elongation at 72 °C for 30 s. The PCR products were digested with 2 U of restriction enzymes.

For cysteine mutations, the digestion products were run on 3% agarose gel (Invitrogen) for 2 h at 120 Volts, with ethidium bromide for viewing. This allowed us to distinguish codon 65 (New England Biolabs, Ipswich, MA, USA) and hemosiderin staining patterns, biopsies were taken at two different contiguous sites for initial and end-point samples, respectively.

Biopsy handling: all patients were treated with subcutaneous local administration of 1% sterile xilocaine. After 10 min, an approximate 12 mm long and 3 mm wide rectangle of tissue was excised to include the surrounding intact skin, the ulcer edge, and the ulcer base. In order to compare changes on both anatomic and hemosiderin staining patterns, biopsies were taken at two different contiguous sites for initial and end-point samples, respectively.

Operational protocol: the product, a gel containing bovine LFR liposomatized to 3%, placed on a 15x20 cm sterile paraffin dressing (tulle gras) made of open weave gauze, with 0.5% chlorhexidine acetate, an antiseptic with a broad spectrum (Bactigras® plaque, Smith and Nephew), was locally applied every day for four weeks (first end point).

It was applied twice a week during the second and third months using an additional compression by means of a multilayer bandage from the very first day, assembled with 3 short 8 cm and 10 cm elastic bandages (Fisiodur®, Zuccari srl, Trento, Italy). The multilayer bandage was applied in a figure-of-eight with turns that regularly crossed one another, with a resting pressure of 40 mmHg and 5-7 mmHg of static stiffness, as previously described.

At each medication session, the ulcer was cleaned using gauzes impregnated with Prontosan® solution (B. Braun Medical Inc., Bethlehem PA, USA) followed by administration of simple occlusive medication.

Figure 2. (A) Patient’s leg with (B) schematic representation of cylindrical volume of each area (1-4). Modified from Rossi et al.

Figure 3. Belczak’s model of goniometry.
showed a starting point with an average intensity of 18.7 and decreased to an average intensity of 7.2 at week 12 (P<0.001) (Figure 5). An approximately 50% decrease in color intensity was observed at Week 4.

Measurement of the area of the ulcer
The area of the ulcer and the scarring rate were checked at study start and at weekly intervals, and observations were recorded. During the initial control, dimensions of ulcers ranged from 3.3 to 23.6 cm. In 8 of 9 patients (9 of 10 ulcers), the area involved decreased significantly (P<0.001) (Table 4 and Figure 6), and in 7 patients, the healing rate reached 80% of the ulcers at the 6-month follow up (Table 5).

Only one patient, who had abandoned the trial, showed a transient increase in the size of the surface of the ulcer, which returned to baseline at Month 6.

Volumetric perimeter: control of edema
Perimetral control of foot and leg was transformed to volume in cm³ as previously described.18-20 With the exception of case no. 3437 (corresponding to the patient with bilateral ulcers) whose values were approximately 9500 cm³, the remaining cases presented values ranging from 3000 cm³ to 5000 cm³ and a mild decrease in the edema volume was observed (Table 6).

Goniometry was measured at baseline and after 30 days to check flexion (flx) and extension (ext) movements. A favorable evolution of the tibioastragaline joint could be observed at the expense of an increase in flexor and extensor excursions without any additional treatment (Table 7).

Pain and chronic lower limb venous insufficiency controls
We used the numerical Likert scale, most commonly seen as a 5 point scale (0=no pain, 5=worst possible pain). In 5 patients, the maximum level of pain (grade 5) was observed at the initial control; this was later reduced to grade 1 after four weeks of treatment. As far as the remaining patients are concerned, the level of the Likert scale diminished 1 point during the same period (Table 8). The survey of quality of life (CIVIQ), the baseline control and the tests performed during Weeks 4, 8 and 12 showed an improvement at all levels. It could be observed that, at all times, the average scoring of the CIVIQ scale (total score) in patients with ulcers closed at Week 12 was lower than the average scoring in patients with unclosed ulcers (P<0.05) (Table 9).

Blood tests: hematimetric and iron metabolism profiles
Normal results of basal control (1st) and after four weeks (2nd) of treatment on hematimetric parameters and platelet counts were observed in all cases (data not shown), and iron metabolism profile (Table 10). Interestingly, while transferrin sat (%) decreased in 7 of 9 cases, ferritin increased in 6 of 9.

HFE genotyping
Only one of the 9 patients (case no. 3334) was heterozygous for the mutant H63D gene (Table 10). Coincidentally, the patient presented a high level of ferritin (222 and 244 µg/mL).

Table 1. Main features of patients’ lesions. No patients were previously treated by surgical or sclerotherapy procedures.

| Case no. | Laterality | Duration CVI (months) | Duration dyschromia (months) | Interval (months) | Duration ulcer age (months) | Primary or recurrent | Cavus and/flat feet | BMI |
|----------|------------|----------------------|-----------------------------|------------------|---------------------------|---------------------|------------------|-----|
| 3446     | R          | 180                  | 22                          | 20               | 2                         | P                   | FC               | Normal |
| 3437     | R          | 180                  | 60                          | 24               | 36                        | R                   | FC               | OB.3 |
| 3437     | L          | 180                  | 60                          | 30               | 30                        | R                   | FC               | OB.3 |
| 3283     | L          | 336                  | 36                          | 34               | 2                         | R                   | FC               | OB.1 |
| 3334     | R          | 276                  | 48                          | 46               | 2                         | R                   | FC               | Over weight |
| 3161     | L          | 192                  | 84                          | 36               | 48                        | R                   | Normal           | Normal |
| 3441     | L          | 60                   | 54                          | ---              | 54                        | P                   | FF               | Normal |
| 3451     | R          | 48                   | 15                          | 2                | 13                        | P                   | FF               | OB.2 |
| 3274     | L          | 560                  | 60                          | 57               | 3                         | P                   | FF               | OB.2 |
| 3449     | R          | 360                  | 240                         | 236              | 4                         | R                   | FC               | Normal |

R, right; L, left; CVI, chronic venous insufficiency; P, primary; R, recurrent; BMI, body mass index; OB, obesity.
Ecodoppler for this patient evidenced reflux on the 3 systems, superficial, perforating and deep reflux mentioned above.

Biopsy histochemistry

Biopsy features of borders and ulcer bed: samples of two control biopsies (initial and after 4 weeks of treatment) were obtained from the perulcerous area in 10 ulcers, and additional samples from the ulcer bed were obtained in another 2. Histological features (Figure 7) and hemosiderin staining (Figure 8) were evaluated before and after treatment. Before treatment, the histological analysis showed the presence of fibrin cuffs, small vessels, and extravasation of red blood cells, fibrosis and a chronic inflammatory pattern (Figure 7A). Perls’ Prussian blue staining showed superficial and deep high cumuli of hemosiderin in the border and fundus of the ulcer (Figure 8A). After four weeks of treatment, extravasated red blood cells and fibrosis were still present; however, certain neovascular structures as well as a repairing inflammatory pattern were observed (Figure 7B). In some cases, Perls’ Prussian blue staining seemed to have decreased (Figure 8B).

**Discussion**

Ochre dermatitis is a secondary pigmentary disorder of venous stasis in which the increase in intravascular pressure and endothelial alterations cause extravasations of erythrocytes, hemosiderin-laden macrophages, and melanin deposits. It is associated with long-term and high care costs, with an equally high incidence of recurrence, and a significant proportion of negative patient outcomes. In our study, all 9 patients were selected from a previous study because they had ulcers and hemosiderinic dyschromia, both associated to refractory ulcer.

Wound repair depends on neoangiogenesis and activation of a local immune response, as well as on the presence of growth factors, including epidermal growth factor, transforming growth factor β, and basic fibroblast growth factor. It has been recently suggested that systemic or topical drugs acting in the wound repair and regeneration processes could be promising and useful agents in the treatment of chronic venous ulcers. However, in a previously reported systematic review performed by Bradley et al., 16 randomized controlled trials were identified that compared topic agents (growth factors, cell suspensions, free-radical scavengers) versus placebo for treating CVI ulcers, concluding that there was insufficient evidence to recommend any particular agent.

The main finding was that topical application of liposomated LFR allowed a fast and progressive

| Time (months) | Number closed lesions | Total |
|---------------|-----------------------|-------|
| 1             | 1/10                  | 1     |
| 3             | 2/10                  | 3     |
| 6             | 6/10*                 | 9     |

*One patient left the study.
reduction in the dimensions of the area of the ulcer in 9 of 9 patients and complete closure in 7 of 9 cases. The 90 days of evolution evidenced an important improvement in the injuries, with a reduction in the intensity of the brown color of the spot (9 of 9) and time to complete scarring ranging from 15 to 180 days (7 of 9). It is important to emphasize that the patients belonged to the group of refractory cases included in the previous study already mentioned. This assay showed that 50% of ulcers showed complete closure using medical compression stockings, and 67% of complete closure with multilayer bandages, after 180 days.

One of the most remarkable findings was the significant decrease, in all cases, of the brown color of the HD and the size of the ulcerous areas (Figures 5 and 6), with a concomitant goniometric improvement (Table 7), and complete closure of lesions in 7 cases after six months of treatment. The rate of healing was independent of baseline or recurrent ulcers (Figure 5).

In all patients, clinical improvement of the wounds (10 ulcers) was associated with a significant decrease in pain and improvement in quality of life, except in one case (*case no. 3161) due to a domestic accident on the lesion, which showed no clinical improvement and led to the patient discontinuing treatment (Figure 6, Tables 8 and 9). All biopsies showed changes in cytological patterns (Figure 7). In several cases, a decrease was seen in the high level of stain-

Table 6. Edema control in cm³: volumetric variation in leg edemas.

| Case no. | Basal | Week 1 | Week 2 | Week 3 | Week 4 | Week 8 | Week 12 |
|----------|-------|--------|--------|--------|--------|--------|--------|
| 3446     | 4227  | 4127   | 4089   | 4072   | 3958   | 3932   | 3886   |
| 3437     | 9457  | 9409   | 9678   | 9623   | 9562   | 9549   | 9605   |
| 3437L    | 9963  | 9856   | 9777   | 9670   | 9581   | 9588   | 9540   |
| 3283     | 4125  | 4122   | 4092   | 4061   | 4011   | 3999   | 3880   |
| 3334     | 4747  | 4680   | 4565   | 4548   | 4495   | 4424   | 4366   |
| 3161     | 3163  | 3056   | 3143   | 3124   | 3125   | 3028   | 3098   |
| 3441     | 4149  | 4011   | 4020   | 3977   | 3959   | 3884   | 3892   |
| 3451     | 4480  | 4314   | 4241   | 4204   | 4115   | 4097   | 4161   |
| 3274     | 4261  | 4008   | 3878   | 4129   | 4114   | 4059   | 3993   |
| 3449     | 4737  | 4512   | 4498   | 4451   | 4388   | 4275   | 4174   |

R, right; L, left.

Table 7. Baseline-final goniometry. Goniometric values before and after 30 days of treatment.

| Case no. | BG (flx) | FG (flx) | BG (ext) | FG (ext) |
|----------|----------|----------|----------|----------|
| 3446     | 12°      | 12°      | 30°      | 42°      |
| 3437     | 10°      | 10°      | 22°      | 25°      |
| 3437L    | 9°       | 10°      | 22°      | 24°      |
| 3283     | 5°       | 12°      | 25°      | 35°      |
| 3334     | 10°      | 12°      | 30°      | 35°      |
| 3161     | 10°      | 12°      | 19°      | 28°      |
| 3446L    | 3°       | 12°      | 37°      | 40°      |
| 3451     | 9°       | 12°      | 22°      | 24°      |
| 3274     | 10°      | 11°      | 20°      | 23°      |
| 3449     | 9°       | 10°      | 15°      | 30°      |

R, right; L, left; BG, baseline; FG, final goniometry; flx, flexion; ext, extension.

Figure 5. Variation in brown color scale values during the treatment.

Figure 6. Ulcer’s areas diminution during six weeks of follow up.
ing for HS in periulcerous and ulcer fundus biopsies present during the initial control (Figure 8) and this associated with a significant improvement in the edema and ulcerous areas (Figure 9) after treatment.

Iron deposits in the skin of patients with CVI cause readily visible HD (brown colored dermal areas) that always surrounds ulcers. The origin of increased iron loads in these lesions lies in the extravasations of red blood cells during significant venous stasis. Erythrocytes are degraded by resident dermal macrophages, and iron is incorporated into ferritin which, in time, changes to HS according to progressive iron overload. Furthermore, the urinary excretion of hemosiderin described in these patients suggests that the phenomenon of leg hemosiderin deposits could be of significance on the entire body. However, in contrast with this hypothesis, in 1988 Ackermann found a 20-fold higher average concentration of iron in lower limbs affected by venous ulcers as compared to the upper arms of the same subjects.

The distribution of high levels of ferritin staining in leg ulcers of patients with CVI were reported to be located intra and extracellular in the matrix, as compared with normal skin tissue with considerably less alterations or non-evident alterations at all. However, the systemic parameters of iron metabolism observed in our study (Table 7) did not seem to influence either the severity of HD nor the evolution of treatment with local LFR. Furthermore, the abnormal levels of ferritin observed in some patients did not limit the previously mentioned improvement in the ulcers. However, it is important to note that potential co-morbidities could be associated to systemic iron overload. One case that presented an altered reflux caused by the combination of the three systems associated with a severe hemodynamic condition was also a carrier of an HFE gene mutation (heterozygous), evidencing high levels of serum ferritin (222 and 244 ng/mL), and suffered a sudden death. In another case with elevated serum ferritin (485 and 355 ng/mL) the patient experienced heart insufficiency and later stroke. Finally, the patient with bilateral ulcers also exhibited high serum ferritin values (233 and 251 ng/mL).

We still do not know with certainty if ferritin could constitute a prognostic evolutive parameter, but its association to the clinical evolution observed in 3/9 patients suggests that it should be included in follow-up protocols.

Because all parameters studied including ulcer lesion features, as well as quality of life (CIVIQ) and pain (Likert’s scale) were improved after treatment, topic application of liposomed LF could be a new therapeutic strategy, particularly in patients with refractory ulcers and HD associated secondary to chronic venous insufficiency.

### Table 8. Pain control using the Likert scale comparing baseline values with those obtained at Week 4.

| Case no. | Baseline | Week 4 |
|----------|----------|--------|
| 3446     | 1        | 1      |
| 3437     | 2        | 1      |
| 3283     | 3        | 2      |
| 3334     | 3        | 2      |
| 3161*    | 2        | 3      |
| 3441     | 5        | 2      |
| 3451     | 5        | 1      |
| 3274     | 2        | 1      |
| 3449     | 5        | 1      |

R: right; L: left. *One patient left the study.

### Table 9. Positive chronic lower limb venous insufficiency score: variation between baseline and final values were observed in all cases except in one patient (*) who discontinued treatment.

| Case no. | Baseline | Final | B-F |
|----------|----------|-------|-----|
| 3446     | 35       | 33    | 2   |
| 3437     | 83       | 75    | 8   |
| 3283     | 66       | 59    | 7   |
| 3334     | 53       | 47    | 6   |
| 3161*    | 49       | 53    | -4  |
| 3441     | 73       | 60    | 13  |
| 3451     | 89       | 80    | 9   |
| 3274     | 67       | 60    | 7   |
| 3449     | 71       | 66    | 5   |

R, baseline; F, final. *One patient left the study.

Figure 7. (A) Histological features before treatment: presence of fibrin sleeves, small vessels, extravasations of red blood cells, fibrosis, chronic inflammatory pattern. (B) Histological features after treatment (4 weeks): presence of new vascular structures, extravasations of red blood cells, fibrosis and granulation tissue-granulation, chronic repairing inflammatory pattern.

Figure 8. Baseline sample (A) showed high hemosiderin concentration (local iron overload) with (B) an evident reduction in hemosiderin staining after four weeks of treatment.
As regards its iron binding properties, LFR differs from serum transferrin in its higher iron binding affinity and unique ability to retain iron over a broad pH range. The protective effects of topical LFR on induced dermatological allergic process was demonstrated experimentally. Similar results were obtained in a study carried out on human volunteers, treated by topical administration of the contact allergen and using purified recombinant human LFR. Although originally identified as an abundant protein in milk secretions, LFR is mainly expressed by surface epithelia and secreted into the mucosal environment. However, further research is needed to clarify whether local iron mobilization, free radical scavenging and induction to tissue repair are simultaneously staged by the multiple properties of LF.

**Conclusions**

Our results suggest that the topical use of LFR could be a potential non-invasive therapeutic tool that favors clearance of HD and a faster closure of ulcers, with concomitant relief or disappearance of pain, and consequent improvement in quality of life in patients with chronic venous insufficiency. Further research is needed to confirm these results by prospective randomized controlled studies.

**References**

1. Raju S, Neglen P. Chronic venous insufficiency and varicose veins. N Engl J Med 2009;360:2319-27.
2. Ackerman Z, Seidenbaum M, Loewenthal E, Rubinow A. Overload of iron of patients with varicose ulcers: possible contributing role of iron accumulation in progression of the disease. Arch Dermatol 1988;124:1376-8.
3. Allegra C, Antignani PL, Bergan JJ, et al. International Union of Phlebology Working Group. The “C” of CEAP: suggested definitions and refinements: an International Union of Phlebology conference of experts. J Vasc Surg 2003;37:129-31.
4. Piotrowicz R, Grzela T, Jawień A, Kuligowska-Prusiska M. Urine haemosiderin: a marker of chronic venous insufficiency. Acta Angiol 2009;15:101-7.
5. Weintraub L, Demis D, Conrad M, Crosby W. Iron excretion by the skin selective localization of iron in epithelia cells. Am J Pathol 1965;46:121-7.
6. Bissett DL, Chatterjee R, Hannon DP. Chronic ultraviolet radiation induced increase in skin iron and the photoprotective effects of topically applied iron chelators. Photochem Photobiol 1991;54:215-23.
7. Takeshita K, Takajo T, Hirata H, et al. In vivo oxygen radical generation in the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study. J Invest Dermatol 2004;122:1463-70.
8. Gira AK, Casper KA, Otto KB, et al. Induction of interferon regulatory factor 1 expression in human dermal endothelial cells by interferon-gamma and tumor necrosis factor-alpha is transcriptionally regulated and requires iron. J Invest Dermatol 2003;121:1191-6.
9. Bhaisin G, Kausar H, Sarwar Alam M, Athar M. Progressive iron overload enhances chemically mediated tumor promotion in murine skin. Arch Biochem Biophys 2003;409:262-73.
10. Chevrant-Breton J, Simon M, Bourel M, Ferrand B. Cutaneous manifestations of...
idiopathic hemochromatosis. Study of 100 cases. Arch Dermatol 1977;113:161-5.
11. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005;42:309-14.
12. Valenti P, Berluzzi F, Conte MP, et al. Lactoferrin functions: current status and perspectives. J Clin Gastroenterol 2004;38 Suppl 6:S127-9.
13. Tang L, Wu JJ, Ma Q, et al. Human Lactoferrin stimulates skin keratinocyte function and wound re-epithelialization. Br J Dermatol 2010;163:38-47.
14. Engelmayr J, Blezinger P, Varadhachary A. Talactoferrin stimulates wound healing with modulation of inflammation. J Surg Res 2008;149:278-86.
15. Brizzio E, Blättler W, Rossi G, et al. Healing venous ulcers with different modalities of leg compression. Unexpected findings of a pilot study. Phlebologie 2006;35:249-55.
16. Brizzio E, Amsler F, Lun B, Blättler W. Comparison of low-strength compression stockings with bandages for the treatment of recalcitrant venous ulcers. J Vasc Surg 2010;51:410-6.
17. Blättler W, Lüscher D, Brizzio E, et al. Healing of chronic venous leg ulcers could be affected by an interaction of the hemochromatosis gene polymorphism HFE H63D with the strength of compression treatment - a re-analysis of patients from previous studies. Wound Repair Regen 2012;20:120-6.
18. Perrin M, Guex JJ. Edema and leg volume: methods of assessment. Angiology 2000;51:9-12.
19. Rossi G, Idiazzabal G. Mathematical model to obtain the volume of the lower limb. Int Angiol 2005;3 Suppl 1:110. [Abstract].
20. Belzak CEQ. Fisiologia do sistema venoso. In: Thomaz JB, Belzak CEQ (eds.). Tratado de flebologia y linfologia. Rio de Janeiro: Editorial Rubio; 2006. pp 37-70.
21. Likert R. A technique for the measurement of attitudes. Archiv Psychol 1932;140:1-55.
22. Launois R, Rebull-Marti J, Henry B. Construction and validation of a quality-of-life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 1996;5:539-54.
23. Boom R, Sol C, Salimans M, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
24. Baptista-González HA, Rosenfeld-Mann F, Trueba-Gómez R, et al. Association of HFE mutations (C282Y and H63D) with iron overload in blood donors from Mexico City. Ann Hepatol 2007;6:55-60.
25. Oliveira VC, Caxito FA, Gomes KB, et al. Frequency of the S65C mutation in the hemochromatosis gene in Brazil. Genet Mol Res 2009;8:794-8.
26. Herrick SE, Sloan P, McGurk M, et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 1992;141:1085-95.
27. Bancroft J, Gamble M (eds.). Theory and practice of histological techniques bankcroft & gamble. 6th edition. London: Churchill-Livingstone, Elsevier Health Sciences; 2008.
28. Brizzio E, Idiazzabal G. Multilayer system. Rev Acta Flebol 2003;3:65-8.
29. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005;15:175-84.
30. Eming SA, Kieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007;127:514-25.
31. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-70.
32. Palfreyman S, King B, Walsh B. A review of the treatment for venous leg ulcers. Br J Nurs 2007;16:S6-14.
33. Bradley M, Cullum N, Nelson EA, et al. Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic. Health Technol Assess 1999;3:1-35.
34. Zamboni P, Scapoli G, Lanzara V, et al. Serum iron and MMP-9 variations in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg 2005;31:644-9.
35. Zamboni P, Izzo M, Tognazzo S, et al. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radic Biol Med 2006;40:1869-73.
36. Zweiman B, Kucich U, Shalit M, et al. Release of lactoferrin and elastase in human allergic skin reactions. J Immunol 1990;144:3953-60.
37. Griffiths CE, Cumberbatch M, Tucker SC, et al. Exogenous topical Lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br J Dermatol 2001;144:715-25.